行情

IMMU

IMMU

Immunomedics
NASDAQ

实时行情|Nasdaq Last Sale

9.40
-1.25
-11.74%
盘前: 9.40 0 0.00% 04:59 04/06 EDT
开盘
9.20
昨收
10.65
最高
9.70
最低
8.80
成交量
966.05万
成交额
--
52周最高
22.22
52周最低
8.80
市值
20.11亿
市盈率(TTM)
-5.0998
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IMMU价格均价为23.55,最高价位35.00,最低价为5.00。

EPS

IMMU 新闻

更多
  • Hedge Funds Are Betting On Immunomedics, Inc. (IMMU)
  • Insider Monkey · 9小时前
  • Marcus Lemonis offers advice to three small business owners
  • CNBC.com · 2天前
  • Lemonis to small biz: Until money's in your bank, stop writing checks
  • CNBC.com · 2天前
  • What exactly is the Defense Production Act?
  • CNBC.com · 2天前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

IMMU 简况

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
展开

微牛提供Immunomedics, Inc.(NASDAQ-IMMU)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IMMU股票新闻,以帮助您做出投资决策。